Skip Navigation


JAC Advance Access originally published online on April 4, 2006
Journal of Antimicrobial Chemotherapy 2006 57(6):1134-1138; doi:10.1093/jac/dkl095
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/6/1134    most recent
dkl095v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Makarov, V.
Right arrow Articles by Möllmann, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Makarov, V.
Right arrow Articles by Möllmann, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Synthesis and antileprosy activity of some dialkyldithiocarbamates

Vadim Makarov1, Olga B. Riabova1, Anatoly Yuschenko2, Nailya Urlyapova2, Adilya Daudova2, Peter F. Zipfel3 and Ute Möllmann3,*

1 Department of Medicinal Chemistry, Research Center for Antibiotics 117105 Moscow, Russia 2 Leprosy Research Institute, 414000 Astrakhan Russia 3 Leibniz Institute for Natural Product Research and Infection Biology—Hans-Knoell Institute D-07745 Jena, Germany

Received 11 January 2006; returned 10 February 2006; revised 24 February 2006; accepted 1 March 2006

*Corresponding author. Tel: +49-3641-656656; Fax: +49-3641-656660; E-mail: ute.moellmann{at}hki-jena.de

Objectives: To investigate the antileprosy potential of a set of original compounds with antimycobacterial activity.

Methods: We developed a facile synthesis of 2-chloro-3-cyano-5-nitropyridine and synthesized a series of 3-cyano-2-dialkyldithiocarbamoyl-5-nitropyridine derivatives. In vivo therapeutic efficacy against Mycobacterium leprae was assessed in the infected mouse footpad model.

Results: The compounds were active in vitro against Mycobacterium smegmatis, Mycobacterium aurum, Mycobacterium vaccae and Mycobacterium fortuitum, with MICs generally in the range of 0.4–6.25 mg/L. Reduction of the bacterial load in vivo in the mouse footpad and toxic side effects were dependent on the individual structure of the compounds and on the doses applied. Compounds 2a, 3a and 3b reduced the number of M. leprae by two orders of magnitude, comparable to the effect of dapsone. Co-administration of compounds 2a and 3a with dapsone synergistically enhanced the activity. In addition, these compounds were well tolerated over the treatment period of 7.5 months.

Conclusions: Individual synthetic dithiocarbamate derivatives have promising antileprosy activity.

Keywords: leprosy , mouse footpad model , antileprosy agents , dithiocarbamates , nitropyridines


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ScienceHome page
V. Makarov, G. Manina, K. Mikusova, U. Mollmann, O. Ryabova, B. Saint-Joanis, N. Dhar, M. R. Pasca, S. Buroni, A. P. Lucarelli, et al.
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Science, May 8, 2009; 324(5928): 801 - 804.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.